Experimental hyperthyroidism in rats suppresses in vitro prostaglandin metabolism in lung and kidney.
Metabolism of prostaglandin (PG) F2alpha and PGE2 was depressed 40--62% in 100,000 g cytoplasmic supernatants of lungs and kidneys prepared from rats made hyperthyroid by 18 daily L(-) thyroxine injections (200microgram, s--c). These hyperthyroid rats had elevated serum thyroxine levels, cardiac hypertrophy and thyroid atrophy. There were no differences in soluble protein concentrations, NAD+ utilisation by endogenous enzymes and substrates, or in the NAD+ dependence of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) between the supernatants prepared from hyperthyroid rats and saline-injected controls. Thyroxine did not inhibit PG metabolism in vitro up to 260 micrometer. These results suggest that thyroxine specifically decreases intracellular levels of PG-metabolising enzymes, especially of the rate-limiting 15-PGDH. Metabolism of PGF2alpha and PGE2 by 15-PGDH was faster in smaller rats and declined with increasing animal weight. These studies imply that some of the clinical features of hyperthyroidism in man might be caused by deficiencies in PG metabolism.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003593:Cytoplasm / Q000201:enzymology / Q000378:metabolism; D006911:Hydroxyprostaglandin Dehydrogenases / Q000378:metabolism; D006980:Hyperthyroidism / Q000139:chemically induced / Q000378:metabolism*; D007668:Kidney / Q000201:enzymology / Q000378:metabolism*; D008168:Lung / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D009243:NAD / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D011458:Prostaglandins E / Q000378:metabolism*; D011460:Prostaglandins F / Q000378:metabolism*; D051381:Rats; D013974:Thyroxine / Q000008:administration & dosage / Q000097:blood
D011458:Prostaglandins E; D011460:Prostaglandins F; D009243:NAD; D006911:Hydroxyprostaglandin Dehydrogenases; D013974:Thyroxine